Advantages and drawbacks of dexamethasone in glioblastoma multiforme
- 11 February 2022
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 172, 103625
Abstract
No abstract availableKeywords
This publication has 278 references indexed in Scilit:
- Glucocorticoid receptor mediated suppression of natural killer cell activity: Identification of associated deacetylase and corepressor moleculesCellular Immunology, 2012
- Glucocorticoid-induced cell death is mediated through reduced glucose metabolism in lymphoid leukemia cellsBlood Cancer Journal, 2011
- Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM)Leukemia, 2010
- Targeting the RTK-PI3K-mTOR Axis in Malignant Glioma: Overcoming Resistance2010
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trialThe Lancet Oncology, 2010
- The Dexamethasone-induced Inhibition of Proliferation, Migration, and Invasion in Glioma Cell Lines Is Antagonized by Macrophage Migration Inhibitory Factor (MIF) and Can Be Enhanced by Specific MIF InhibitorsJournal of Biological Chemistry, 2009
- Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statementThe Lancet Oncology, 2009
- Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancerBritish Journal of Cancer, 2008
- Inflammation and cancerNature, 2002